TO THE EDITOR
Some lymphoproliferative diseases (LPD) are linked to Epstein-Barr virus (EBV) infection. Laboratory diagnosis of this infection is commonly based on serological profiles which are difficult to interpret in immunocompromised patients, whereas the study of clinical samples by morphologists is helpful in assessing the diagnosis of LPD and in situ hybridization can identify infected cells. EBV DNA sequences have been reported to be detected by PCR in plasma or sera of patients with EBV-associated diseases. [1] [2] [3] A retrospective analysis of banked serum samples was carried out to check for the presence of EBV DNA by PCR with primers flanking a 186 bp in the BamHI W region as previously described. 2 The results are shown in Table 1 . As recently published, 2, 3 cell-free EBV DNA has never been detected in EBV seronegative and seropositive healthy controls, but was present in 85.5% of patients during the acute phase of infectious mononucleosis (IM); in three cases, a positive PCR signal even preceded the seroconversion. The two patients with fatal IM revealed EBV DNA in their serum 3 and 6 weeks before death. Contrary to the findings of Gan et al, 1 more than 50% of patients with nasopharyngeal carcinoma harbored EBV DNA, while less than 30% of patients with Hodgkin's disease (HD) showed amplified viral sequences. Mounier et al 4 have Table 1 Presence of EBV DNA determined by PCR in serum recently reported an EBV reactivation associated with HD relapse. Plasmatic PCR was positive for EBV DNA.
The main message of this study concerns transplanted patients who developed LPD. In our series of bone marrow and liver recipients, LPD occurred during the early post-transplantation period (1-3 months) . In three out four bone marrow and two out four liver recipients, EBV DNA was isolated from serum a few weeks before the appearance of lymphoproliferative lesions. In the fourth case of bone marrow and the third case of liver recipient, EBV DNA was detected at the onset of LPD. In kidney graft recipients, LPD occurred 5, 7 and 39 months after transplantation, while EBV DNA presence was confirmed several weeks before the clinical symptoms became manifest. The high overall percentage of PCR positivity (91%) for EBV DNA isolation in serum and the occurrence of subsequent LPD in transplanted patients appear to be closely related.
In conclusion, the search for EBV DNA by PCR in serum is relevant to predict LPD occurrence, especially in immunocompromised patients. Follow-up of viremia may help to monitor antiviral therapy and/or immunosuppressive drugs. 
Acknowledgements

